NE BUSINESS BUREAU
AHMEDABAD, JULY 15
City-based drug firm Zydus Cadila on Wednesday said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D.
In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.
The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that “the adaptive phase I/II dose-escalation, the multi-centric study will assess the safety, tolerability, and immunogenicity of the vaccine.”
Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender – the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.
It got approval a few days after India’s first indigenous COVID-19 vaccine candidate COVAXIN, developed by city-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India.
